<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1038/s41598-019-47058-y</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">41598</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title><abbrev-journal-title abbrev-type="publisher">Sci Rep</abbrev-journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s41598-019-47058-y</article-id><article-id pub-id-type="manuscript">47058</article-id><article-id pub-id-type="doi">10.1038/s41598-019-47058-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/631/208/205</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/692/699/255/2514</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/631/208/205</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/692/699/255/2514</subject></subj-group><subj-group subj-group-type="TechniquePath"><subject>/38/77</subject></subj-group><subj-group subj-group-type="NatureArticleTypeID"><subject>article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Genetic mutations in NF-κB pathway genes were associated with the protection from hepatitis C virus infection among Chinese Han population</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><name><surname>Yue</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Tian</surname><given-names>Ting</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Wang</surname><given-names>Chunhui</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Fan</surname><given-names>Haozhi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au5"><name><surname>Wu</surname><given-names>Jingjing</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au6"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3352-4690</contrib-id><name><surname>Wang</surname><given-names>Jinke</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" id="Au7"><name><surname>Li</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au8"><name><surname>Xia</surname><given-names>Xueshan</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" id="Au9"><name><surname>Zhang</surname><given-names>Amei</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" id="Au10"><name><surname>Yu</surname><given-names>Rongbin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au11"><name><surname>Zhang</surname><given-names>Yun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au12"><name><surname>Huang</surname><given-names>Peng</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="corresp" rid="IDs4159801947058y_cor12">n</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1799 0784</institution-id><institution-id institution-id-type="GRID">grid.412676.0</institution-id><institution content-type="org-division">Department of Infectious Diseases</institution><institution content-type="org-name">The First Affiliated Hospital of Nanjing Medical University</institution></institution-wrap><addr-line content-type="postcode">210029</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution content-type="org-division">Department of Acute Infectious Disease Control and Prevention</institution><institution content-type="org-name">Jiangsu Province Center for Disease Prevention and Control</institution></institution-wrap><addr-line content-type="postcode">210009</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution content-type="org-division">Institute of Epidemiology and Microbiology</institution><institution content-type="org-name">Eastern Theater Command Centers for Disease Control and Prevention</institution></institution-wrap><addr-line content-type="postcode">210002</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9255 8984</institution-id><institution-id institution-id-type="GRID">grid.89957.3a</institution-id><institution content-type="org-division">Department of Epidemiology and Biostatistics</institution><institution content-type="org-name">Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University</institution></institution-wrap><addr-line content-type="postcode">211166</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1761 0489</institution-id><institution-id institution-id-type="GRID">grid.263826.b</institution-id><institution content-type="org-division">State Key Laboratory of Bioelectronics</institution><institution content-type="org-name">Southeast University</institution></institution-wrap><addr-line content-type="postcode">210096</addr-line><addr-line content-type="city">Nanjing</addr-line><country country="CN">China</country></aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8571 108X</institution-id><institution-id institution-id-type="GRID">grid.218292.2</institution-id><institution content-type="org-division">Faculty of Life Science and Technology</institution><institution content-type="org-name">Kunming University of Science and Technology</institution></institution-wrap><addr-line content-type="postcode">650500</addr-line><addr-line content-type="city">Kunming</addr-line><country country="CN">China</country></aff></contrib-group><author-notes><corresp id="IDs4159801947058y_cor12"><label>n</label><email>huangpeng@njmu.edu.cn</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>7</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>9</volume><issue seq="36683">1</issue><elocation-id>10830</elocation-id><history><date date-type="registration"><day>11</day><month>7</month><year>2019</year></date><date date-type="received"><day>31</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2019</year></date><date date-type="online"><day>25</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><p id="Par1">Host genetic polymorphism is one of major unalterable major factors for HCV infection. NF-κB proteins play multiple roles in immune response and involve in HCV infection and progression. This study was conducted to explore the relationship between single nucleotide polymorphisms (SNPs) in NF-κB pathway and the susceptibility as well as resolution of HCV infection. A total of 1642 Chinese subjects were enrolled in the study, including 963 uninfected control cases, 231 cases with spontaneous viral clearance and 448 cases with persistent HCV infection, and four SNPs (Rel rs842647, NF-κB2 rs12769316, RelA rs7101916, RelB rs28372683) were genotyped by TaqMan assay among them. Potentially functional polymorphisms were analyzed using online bioinformatics tools. The logistic analyses results indicated that RelA rs7101916 T allele (<italic>P</italic><sub><italic>Bonferroni</italic></sub> = 0.016) and RelB rs28372683 A allele (<italic>P</italic><sub><italic>Bonferroni</italic></sub> = 4.8e-5) were associated with an decreased risk of the susceptibility to HCV infection among Chinese Han population, which were consistent with the results of cumulative effects and haplotype analysis. The <italic>silico</italic> analysis of SNPs function suggested that the genetic variation of rs7101916 and rs28372683 could influence gene transcriptional regulation and expression, subsequently affecting NF-κB pathway activation and the susceptibility to HCV infection. This study firstly reported that the carriage of RelA rs7101916 T or RelB rs28372683 A was the potential protective factor against HCV infection among the Chinese population.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">https://doi.org/10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">81773499, 81502853, 81703273, 81473029</award-id><award-id award-type="FundRef grant">61571119</award-id><principal-award-recipient><name><surname>Yue</surname><given-names>Ming</given-names></name></principal-award-recipient><principal-award-recipient><name><surname>Wang</surname><given-names>Chunhui</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation)</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">https://doi.org/10.13039/501100004608</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">BK20171054, BK20151026</award-id><principal-award-recipient><name><surname>Yue</surname><given-names>Ming</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution>Innovative Team of Jiangsu Province</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">https://doi.org/10.13039/501100005065</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">CXTDA2017023</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Jun</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>Nature Research</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>Yes</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>7</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>11</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>NonStandardArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/41598_2019_Article_47058.pdf</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Science, Humanities and Social Sciences, multidisciplinary</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Science, Humanities and Social Sciences, multidisciplinary</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Science, multidisciplinary</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Science (multidisciplinary)</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Over 185 million people worldwide suffer from hepatitis C virus (HCV) infection<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. HCV infection is usually asymptomatic and will develop some hepatic and extrahepatic disorders, including liver cirrhosis, hepatocellular carcinoma, non-Hodgkin’s lymphoma, cryoglobulinemia, etc<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. In recent years, due to the highly effectiveness of clinical applications of novel direct-acting antiviral drugs (DAAs), the expectation for a cure for hepatitis C has increased dramatically<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. However, many significant challenges remain, including undetected most HCV cases, resistance-associated variants (RAVs) of HCV protease inhibitors, and HCV reinfection after cure of chronic hepatitis C, etc<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. A critical measure in the global control of hepatitis C is identifying atrisk persons for HCV<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">Host genetic polymorphism is one of unalterable major risk factors for HCV infection. Genome-wide association study (GWAS) found that single nucleotide polymorphisms (SNPs) on the <italic>IL28B</italic> gene are associated with HCV clearance<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. In addition, various human leukocyte antigen (HLA) alleles involved in the immune response have been shown to be associated with spontaneous clearance of HCV infection, and may even predict HCV treatment response<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Nuclear factor κB (NF-κB) was first discovered as a nuclear factor binding to a κ enhancer of the immunoglobulin κ light chain gene of activated B cells<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. NF-κB can be found in almost all animal cell types and is a key an important regulator of the anti-pathogen immune response, inflammatory reaction, cell proliferation and survival<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. It subsequently became clear that NF-κB is involved in signal-induced expression of hundreds of genes<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. The NF-κB transcription factor family is composed of five DNA binding proteins: NF-κB1 (p50, p105), NF-κB2 (p52, p100), RelA (p65), RelB, and c-Rel<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. These proteins can form homodimers or heterodimer with widely different transcriptional activities and their expression levels show differences in event and tissue-specific expression patterns in response to a different stimulus<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. NF-κB remains in an inactive form complexes with inhibitors of κB (IκBs), of which mainly includes IκBα, IκBβ, and IκBε<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Different IκBs control the regulation of different tissues by inhibiting specific NF-κB dimers<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. These inhibitory proteins can be phosphorescent and degraded by IκB kinase (IKK) in a critical event leading to NF-κB activation<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par4">A variety of external stimulants can activate NF-κB signaling pathway, including viruses, bacterial lipopolysaccharide, proinflammatory cytokines and stress-inducing agents, followed by the promotion of the expression of hundreds of genes. Most of target genes encoded proteins, including many cytokines, chemokines and receptors, participate in the process of immune recognition and adhesion, antigen presentation in the host innate and adaptive immune response<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. NF-κB also can be activated by HCV and stimulates the production of IL-1, IL-6, lymphotoxin, and IFN-γ<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Due to the extensive influence, NF-κB can be regarded as the central mediator of the immune response<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. The immune response to HCV is mainly regulated by NF-κB and interferon-signaling pathways<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Therefore, abnormal activation or regulation of NF-κB signaling pathway genes are associated with various immune-related diseases, including some infectious diseases, autoimmune diseases, chronic obstructive pulmonary disease, and cancer<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR18">18</xref></sup>.</p><p id="Par5">Many SNPs in the NF-κB signaling pathway genes have been identified involved in many diseases. Our previous studies found that the nearby RelA rs11820062-A and NFKB1 rs28362491-D are significantly associated with an increased HCV susceptibility within a high-risk Chinese population and they may alter the binding of transcription factor (TF) and transcriptional regulation of the corresponding gene<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. In addition, in the previous bioinformatics analyses, rs11820086 also may be related to RelA mRNA expression in immortalized B-lymphocytes<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and conferred increased susceptibility to chronic kidney disease<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> and schizophrenia<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Other researches have suggested NF-κB1 rs230530, NF-κB2 rs1056890 and other SNPs are linked to many diseases, such as liver cancer<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, alcohol addiction<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, the inflammatory responses in the development of lymphedema following breast cancer treatment<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, the development of multiple myeloma<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> and other immune-related diseases<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. No genetic association studies of rs7101916 was reported.</p><p id="Par6">Considering the role of NF-κB signaling pathway genes in the innate and adaptive immune response to HCV infection, our previous studies deserve continuing, in-depth investigation. Therefore, this case-control study aims to further explore the relationships between NF-κB pathway genes’ SNPs: Rel rs842647, RelA rs7101916, NF-κB2 rs12769316 and RelB rs28372683, and HCV infection outcomes within a high-risk Chinese population.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec3"><title>Ethics statement</title><p id="Par7">This study was given permission by the institutional review board of Nanjing Medical University and was implemented in accordance with the ethical guidelines of the Declaration of Helsinki<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Written informed consent was collected from all participants before entering into the study.</p></sec><sec id="Sec4"><title>Study population</title><p id="Par8">This study conducted a case-control study with a total of 1642 subjects, including 693 hemodialysis (HD) subjects recruited from nine hospital hemodialysis centers in southern China from October 2008 to May 2015, and 949 paid blood donors recruited from six villages within Zhenjiang City from October 2008 to September 2016. Subjects co-infected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV), or suffered from autoimmune, alcoholic or metabolic liver diseases, or received polyethylene glycol (Peg) IFN-α plus ribavirin (RBV), or oral DAAs treatment were excluded from this study. The flowchart of the selection of patients included in the study was shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption xml:lang="en"><p>Flowchart of the selection of patients included in the study.</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41598_2019_47058_Fig1_HTML.png"/></p></fig></p><p id="Par9">The subjects were put into three groups depending on their anti-HCV and HCV RNA results. Group A was comprised of HCV-uninfected controls with seronegative anti-HCV and seronegative HCV RNA. Group B was composed of spontaneous clearance subjects with seropositive anti-HCV and seronegative for HCV RNA. Group C was composed of persistent infection patients with seropositive anti-HCV and seropositive HCV RNA. Individuals in group B or group C were defined as infected individuals. All results of serologic tests were verified by three separate experiments within the 12 consecutive months. The control subjects (group A) were matched to the infected individuals (group B or group C) by age (5-year interval), gender and the village of recruitment.</p><p id="Par10">Structured questionnaires were administered to trained interviewers for interviews carried out with every participant to collect the demographic information, the environmental exposure history and the medical history of HCV infection. Quality control program was established to guarantee the reliability of all data obtained.</p></sec><sec id="Sec5"><title>Viral testing</title><p id="Par11">Venous blood samples were drawn from each participant after the interview and stored at −80 °C after centrifugation until the experiment. Anti-HCV antibodies were detected using a third-generation enzyme-linked immunosorbent assay (ELISA: Diagnostic Kit for Antibody to HCV 3.0 ELISA, Intec Products Inc, Xiamen, China) according to the manufacturer’s instructions. HCV RNA was extracted using Trizol LS reagent (Takara Biotech, Tokyo, Japan), and reverse transcription polymerase chain reaction (PCR; Takara Biotech) was performed. The Murex HCV Serotyping 1–6 Assay ELISA kit (Abbott, Wiesbaden, Germany) was used to detect type-specific antibodies of various HCV genotypes<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.</p></sec><sec id="Sec6"><title>SNPs selection</title><p id="Par12">TagSNP (Rel rs842647) was selected using Haploview software (version 4.2; Broad Institute, Cambridge, MA, USA) on the basis of the data of HapMap Phase II CHB (Chinese in Beijing) obtained from 1000 Genomes Project resources (<ext-link xlink:href="http://www.1000genomes.org/" ext-link-type="url">http://www.1000genomes.org/</ext-link>). RelA rs7101916, NF-κB2 rs12769316 and RelB rs28372683 were selected based on the functional prediction for possible transcription factor binding sites or miRNA binding sites using National Institute of Environmental Health Sciences (NIEHS) (<ext-link xlink:href="https://www.niehs.nih.gov/" ext-link-type="url">https://www.niehs.nih.gov/</ext-link>), Search RegulomeDB (<ext-link xlink:href="http://www.regulomedb.org/" ext-link-type="url">http://www.regulomedb.org/</ext-link>) and based on the related literatures in which SNPs were reported to be associated with immune-related diseases. In addition to the above strategies, the minor allele frequency (MAF) of the candidate SNP must be more than 5% among the Chinese Han population.</p></sec><sec id="Sec7"><title>Genotyping assays</title><p id="Par13">Genomic DNA was extracted from leukocytes derived from subjects’ blood samples using protease K digestion, phenol-chloroform extraction and ethanol precipitation. Before the genotyping, we used ultraviolet spectrophotometer (UV-2700220V CH) to detect the concentration and purity of DNA, and excluded OD<sub>260</sub>/OD<sub>280</sub> &lt; 1.75, OD &lt; 100 ng/ul sample. Candidate SNPs were genotyped by using the TaqMan allelic discrimination assay on an ABI 7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The primers and probe sequences for candidate SNPs are shown in Supplementary Table <xref ref-type="supplementary-material" rid="MOESM1">1</xref>. The experimenters were blind to the subjects’ demographical and clinical data. Quality control was performed using two negative controls and two positive controls included in each 384-well plate to identify the agent or system contaminations. The success rates of genotyping for four SNPs were all above 99.8% and a 100% concordance rate was showed in 10% random selected samples for repeated testing. The genotyping results were analyzed using Sequence Detection System software (SDS, version 2.3; Applied Biosystems, Foster, CA, USA).</p></sec><sec id="Sec8"><title><italic>In silico</italic> analysis</title><p id="Par14">SNPInfo web server (<ext-link xlink:href="http://snpinfo.niehs.nih.gov/" ext-link-type="url">http://snpinfo.niehs.nih.gov/</ext-link>) was run based on the data from HapMap China Han Beijing (CHB) population to predict the impact on genes of potentially functional polymorphisms. The Vienna RNAfold web server (<ext-link xlink:href="http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi" ext-link-type="url">http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi</ext-link>) was used to predict secondary structures of single stranded RNA sequences based on the latest ViennaRNA Package (Version 2.4.4). The secondary structure with the minimum free energy (MFE; i.e. MFE structure) or the minimal base pair distance (i.e. centroid secondary structure) was computed and drew to characterize and compare the the influence on the secondary structure of gene between wild type and mutant type of the polymorphism site. We also carried out the expression Quantitative Trait Loci (eQTL) analysis on the public database Genotype-Tissue Expression (GTEx) Portal (<ext-link xlink:href="http://www.gtexportal.org/home" ext-link-type="url">http://www.gtexportal.org/home</ext-link>) to identify whether this SNP could cause any differential expression in different tissues.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par15">All data were analyzed using Statistical Package for the Social Sciences software (SPSS: version 21.0.0.0; SPSS Institute, Chicago, IL, USA) and Statistical Analysis System software (SAS: version 9.4; SAS Institute, Cary, NC, USA). Demographics data, clinical characteristics and genotype distribution of subjects were compared using one-way analysis of variance (ANOVA), χ<sup>2</sup>-test or Kruskal-Wallis test where appropriate. A goodness-of-fit χ<sup>2</sup> test was used to estimate Hardy-Weinberg equilibrium (HWE) for each SNP among the controls. Linkage disequilibrium (LD) parameters (r<sup>2</sup> and D′) were calculated using Haploview software (version 4.2; Broad Institute, Cambridge, MA, USA). The associations between SNPs with the susceptibility to HCV infection or the spontaneous clearance of HCV infection were estimated by comparing group A v.s. group (B + C) or group B v.s. group C, respectively, and were calculated by binary logistic regression analysis, unadjusted or adjusted for age, gender and route of infection, and were explained by odds ratios (ORs), 95% confidence intervals (CIs) using dominant genetic model ((homozygous type + hybrid type) v.s. wild type). Cumulative effects of combined risk alleles or combined risk genotypes were estimated with logistic regression model, adjusted for gender, age and routes of infection or calculated by the Cochran-Armitage trend test. Haplotype reconstruction was carried out using the PHASE software (version 2.1; UW TechTransfer Digital Ventures, University of Washington, Seattle, WA, USA). <italic>P</italic> &lt;0.05 in a two-sided test was considered statistically significant. Bonferroni correction was utilized to conduct multiple comparisons.</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><sec id="Sec11"><title>Basic characteristics</title><p id="Par16">The demographics and clinical characteristics of all subjects are presented in Table <xref rid="Tab1" ref-type="table">1</xref>. No significant age or gender difference was found among three groups (all <italic>P</italic> &gt; 0.05) or between any two groups (all <italic>P</italic> &gt; 0.05, data not shown). However, the alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels, routes of infection and HCV genotype were significantly different among three groups (all <italic>P</italic> &lt; 0.01) or between any two groups (all <italic>P</italic> &lt; 0.01, data not shown). The allele distribution of four SNPs was in accordance with Hardy-Weinberg equilibrium expectations in the control group (group A: <italic>P</italic> = 0.120 for rs842647, <italic>P</italic> = 0.271 for rs7101916, <italic>P</italic> = 0.153 for rs12769316, <italic>P</italic> = 0.603 for rs28372683).<table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>Demographical and clinical characteristics among HCV control, spontaneous clearance and persistent infection groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Variables</p></th><th><p>Group A (n = 963)</p></th><th><p>Group B (n = 231)</p></th><th><p>Group C (n = 448)</p></th><th rowspan="2"><p><italic>P</italic> value</p></th></tr><tr><th><p>n (%)</p></th><th><p>n (%)</p></th><th><p>n (%)</p></th></tr></thead><tbody><tr><td><p>Age (years, mean ± SD)</p></td><td><p>55.08 ± 11.29</p></td><td><p>56.63 ± 9.26</p></td><td><p>54.74 ± 8.72</p></td><td><p>0.068<sup>a</sup></p></td></tr><tr><td><p>Gender</p></td><td/><td/><td/><td><p>0.694<sup>b</sup></p></td></tr><tr><td><p>   Male</p></td><td><p>357 (37.1)</p></td><td><p>80 (34.6)</p></td><td><p>158 (35.3)</p></td><td/></tr><tr><td><p>   Female</p></td><td><p>606 (62.9)</p></td><td><p>151 (65.4)</p></td><td><p>290 (64.7)</p></td><td/></tr><tr><td><p>   ALT(median(IQR),U/L)</p></td><td><p>10.00 (6.00, 18.00)</p></td><td><p>23.00 (11.00, 40.00)</p></td><td><p>28.00 (17.00, 50.00)</p></td><td><p>&lt;0.001<sup>c</sup></p></td></tr><tr><td><p>   AST (median(IQR), U/L)</p></td><td><p>18.00 (11.00, 24.75)</p></td><td><p>28.00 (17.00, 40.00)</p></td><td><p>34.50 (24.00.50.75)</p></td><td><p>&lt;0.001<sup>c</sup></p></td></tr><tr><td><p>Routes of infection</p></td><td/><td/><td/><td><p>&lt;0.001<sup>b</sup></p></td></tr><tr><td><p>   HD</p></td><td><p>547 (56.8)</p></td><td><p>84 (36.4)</p></td><td><p>62 (13.8)</p></td><td/></tr><tr><td><p>   Blood donation</p></td><td><p>416 (43.2)</p></td><td><p>147 (63.6)</p></td><td><p>386 (86.2)</p></td><td/></tr><tr><td><p>HCV genotype</p></td><td/><td/><td/><td><p>&lt;0.001<sup>b</sup></p></td></tr><tr><td><p>   1</p></td><td><p>—</p></td><td><p>40 (45.5)</p></td><td><p>93 (36.0)</p></td><td/></tr><tr><td><p>   Non-1</p></td><td><p>—</p></td><td><p>27 (30.7)</p></td><td><p>11 (4.3)</p></td><td/></tr><tr><td><p>   Mixed</p></td><td><p>—</p></td><td><p>21 (23.9)</p></td><td><p>154 (59.7)</p></td><td/></tr></tbody></table><table-wrap-foot><p>Abbreviations: SD: standard deviation; ALT, alanine transaminase; AST, aspartate aminotransferase; ANOVA, analysis of variance; HCV, hepatitis C virus; HD, hemodialysis.</p><p>Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients.</p><p><sup>a</sup><italic>P</italic> value of one-way ANOVA among three groups.</p><p><sup>b</sup><italic>P</italic> value of χ<sup>2</sup>-test among three/two groups.</p><p><sup>c</sup><italic>P</italic> value of Kruskal–Wallis test among three/two groups.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Association between <italic>NF-κB</italic> genes polymorphisms and the susceptibility to HCV infection</title><p id="Par17">Genotype distribution of SNPs rs842647, rs7101916, rs12769316 and rs28372683 among three groups is shown in Table <xref rid="Tab2" ref-type="table">2</xref>. It can be seen that the allelic and genotypic frequencies of rs7101916 and rs28372683 were significantly different across the three groups (<italic>P</italic> &lt; 0.05). However, no significant difference was seen in the distribution of rs842647 and rs12769316 genotypes among the three groups. Only genetic dominant model was used for analyze the association between SNPs and the susceptibility to HCV infection, because the number of the subjects carried the minor allele homozygote of two SNPs (rs842647 and rs12769316) among some groups was small (&lt;10) for powerful statistical analysis. As shown in Table <xref rid="Tab3" ref-type="table">3</xref>, before or after adjusting for gender, age, and the route of infection, the results of logistic regression analysis showed that, compared with the major allele homozygote (rs7101916 CC genotype or rs28372683 CC genotype), the carriage of rs7101916 T allele or rs28372683A allele was associated with a decreased risk of the susceptibility to HCV (rs7101916: OR = 0.728, 95% CI = 0.588–0.901, <italic>P</italic> = 0.004; rs28372683: OR = 0.499, 95% CI = 0.366–0.681, <italic>P</italic> = 1.2e-5), and they remained significant after the multiple comparisons using Bonferroni correction (rs7101916: <italic>P</italic> = 0.016; rs28372683: <italic>P</italic> = 4.8e-5).<table-wrap id="Tab2"><label>Table 2</label><caption xml:lang="en"><p>Genotypes distributions of <italic>NF-κB</italic> signaling pathway genes among persistent infection, spontaneous clearance and control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><p>SNPs</p></th><th><p>Genotypes</p></th><th><p>Group A, n (%)</p></th><th><p>Group B, n (%)</p></th><th><p>Group C, n (%)</p></th><th><p><italic>P</italic></p></th></tr></thead><tbody><tr><td rowspan="5"><p>rs842647</p></td><td><p>GG</p></td><td><p>674 (70.0)</p></td><td><p>162 (70.1)</p></td><td><p>310 (69.2)</p></td><td><p>0.648</p></td></tr><tr><td><p>GA</p></td><td><p>271 (28.1)</p></td><td><p>61 (26.4)</p></td><td><p>127 (28.3)</p></td><td/></tr><tr><td><p>AA</p></td><td><p>18 (1.9)</p></td><td><p>8 (3.5)</p></td><td><p>11 (2.5)</p></td><td/></tr><tr><td><p>G allele</p></td><td><p>1619 (84.1)</p></td><td><p>385 (83.3)</p></td><td><p>747 (83.4)</p></td><td><p>0.865</p></td></tr><tr><td><p>A allele</p></td><td><p>307 (15.9)</p></td><td><p>77 (16.7)</p></td><td><p>149 (16.6)</p></td><td/></tr><tr><td rowspan="5"><p>rs7101916</p></td><td><p>CC</p></td><td><p>372 (38.6)</p></td><td><p>108 (46.8)</p></td><td><p>219 (48.9)</p></td><td><p><bold>0.003</bold></p></td></tr><tr><td><p>CT</p></td><td><p>440 (45.7)</p></td><td><p>88 (38.1)</p></td><td><p>176 (39.3)</p></td><td/></tr><tr><td><p>TT</p></td><td><p>151 (15.7)</p></td><td><p>35 (15.2)</p></td><td><p>53 (11.8)</p></td><td/></tr><tr><td><p>C allele</p></td><td><p>1184 (61.5)</p></td><td><p>304 (65.8)</p></td><td><p>614 (68.5)</p></td><td><p><bold>0.001</bold></p></td></tr><tr><td><p>T allele</p></td><td><p>742 (38.5)</p></td><td><p>158 (34.2)</p></td><td><p>282 (31.5)</p></td><td/></tr><tr><td rowspan="5"><p>rs12769316</p></td><td><p>CC</p></td><td><p>679 (70.5)</p></td><td><p>157 (68.0)</p></td><td><p>295 (65.8)</p></td><td><p>0.335</p></td></tr><tr><td><p>CT</p></td><td><p>252 (26.2)</p></td><td><p>65 (28.1)</p></td><td><p>130 (290)</p></td><td/></tr><tr><td><p>TT</p></td><td><p>32 (3.3)</p></td><td><p>9 (3.9)</p></td><td><p>23 (5.1)</p></td><td/></tr><tr><td><p>C allele</p></td><td><p>1610 (83.6)</p></td><td><p>379 (82.0)</p></td><td><p>720 (80.4)</p></td><td><p>0.105</p></td></tr><tr><td><p>T allele</p></td><td><p>316 (16.4)</p></td><td><p>83 (18.0)</p></td><td><p>176 (19.6)</p></td><td/></tr><tr><td rowspan="5"><p>rs28372683</p></td><td><p>CC</p></td><td><p>799 (83.1)</p></td><td><p>204 (88.3)</p></td><td><p>399 (89.1)</p></td><td><p><bold>0.001</bold></p></td></tr><tr><td><p>CA</p></td><td><p>154 (16.0)</p></td><td><p>21 (9.1)</p></td><td><p>47 (10.5)</p></td><td/></tr><tr><td><p>AA</p></td><td><p>9 (0.9)</p></td><td><p>6 (2.6)</p></td><td><p>2 (0.4)</p></td><td/></tr><tr><td><p>C allele</p></td><td><p>1752 (91.1)</p></td><td><p>429 (92.9)</p></td><td><p>845 (94.3)</p></td><td><p><bold>0.010</bold></p></td></tr><tr><td><p>A allele</p></td><td><p>172 (8.9)</p></td><td><p>33 (7.1)</p></td><td><p>51 (5.7)</p></td><td/></tr></tbody></table><table-wrap-foot><p>Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption xml:lang="en"><p>Association between SNP in <italic>NF-κB</italic> signaling pathway genes and the outcomes of HCV infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><p>SNPs</p></th><th><p>Genotypes</p></th><th><p>OR (95% CI)<sup>a</sup></p></th><th><p>P<sup>a</sup></p></th><th><p>OR(95% CI)<sup>b</sup></p></th><th><p>P<sup>b</sup>/P<sup>c</sup></p></th></tr></thead><tbody><tr><td colspan="6"><p><bold>(a) SNPs associated with the susceptibility of HCV infection, Group (B + C)</bold><bold><italic>vs</italic></bold><italic>.</italic><bold>Group A</bold></p></td></tr><tr><td rowspan="2"><p>rs842647</p></td><td><p>GG</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>GA/AA</p></td><td><p>1.023 (0.826–1.267)</p></td><td><p>0.836</p></td><td><p>0.887 (0.705–1.117)</p></td><td><p>0.308/1.232</p></td></tr><tr><td rowspan="2"><p>rs7101916</p></td><td><p>CC</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>CT/TT</p></td><td><p><bold>0.678 (0.555–0.827)</bold></p></td><td><p><bold>1.23e-4</bold></p></td><td><p><bold>0.728 (0.588–0.901)</bold></p></td><td><p><bold>0.004/0.016</bold></p></td></tr><tr><td rowspan="2"><p>rs12769316</p></td><td><p>CC</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>CT/TT</p></td><td><p>1.201 (0.972–1.483)</p></td><td><p>0.090</p></td><td><p>1.167 (0.931–1.464)</p></td><td><p>0.180/0.720</p></td></tr><tr><td rowspan="2"><p>rs28372683</p></td><td><p>CC</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>CA/AA</p></td><td><p><bold>0.618 (0.461–0.827)</bold></p></td><td><p><bold>0.001</bold></p></td><td><p><bold>0.499 (0.366–0.681)</bold></p></td><td><p><bold>1.2e-5/4.8e-5</bold></p></td></tr><tr><td colspan="6"><p><bold>(b) SNPs associated with the spontaneous clearance of HCV infection, Group B</bold><bold><italic>vs</italic></bold><italic>.</italic><bold>Group C</bold></p></td></tr><tr><td rowspan="2"><p>rs842647</p></td><td><p>GG</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>GA/AA</p></td><td><p>1.045 (0.740–1.477)</p></td><td><p>0.802</p></td><td><p>1.041 (0.489–2.218)</p></td><td><p>0.917/3.668</p></td></tr><tr><td rowspan="2"><p>rs7101916</p></td><td><p>CC</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>CT/TT</p></td><td><p>0.918 (0.668–1.262)</p></td><td><p>0.599</p></td><td><p>0.650 (0.331–1.275)</p></td><td><p>0.210/0.840</p></td></tr><tr><td rowspan="2"><p>rs12769316</p></td><td><p>CC</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>CT/TT</p></td><td><p>1.100 (0.784–1.543)</p></td><td><p>0.580</p></td><td><p>0.995 (0.504–1.963)</p></td><td><p>0.988/3.952</p></td></tr><tr><td rowspan="2"><p>rs28372683</p></td><td><p>CC</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td><td><p>—</p></td></tr><tr><td><p>CA/AA</p></td><td><p>0.928 (0.563–1.528)</p></td><td><p>0.736</p></td><td><p>0.683 (0.179–2.599)</p></td><td><p>0.576/2.304</p></td></tr></tbody></table><table-wrap-foot><p>Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients.</p><p>Group (B + C): Infected individuals, including persistent infection group and spontaneous clearance group.</p><p><sup>a</sup>Unadjusted <italic>P</italic> value, odds ratio (OR) and 95% confidence intervals (CI).</p><p><sup>b</sup>The <italic>P</italic> value, odds ratio (OR), 95% confidence intervals (CI) were calculated on the basis of the binary logistic regression model, adjusted by gender, age, route of infection (and HCV genotype) in dominant model (GG vs. GA + AA for rs842647, CC vs. CT + TT for rs7101916, CC vs. CT + TT for rs12769316, CC vs. CA + AA for rs28372683).</p><p><sup>c</sup>Multiple testing: using Bonferroni correction.</p></table-wrap-foot></table-wrap></p><p id="Par18">Further stratification analysis (Table <xref rid="Tab4" ref-type="table">4</xref>) indicated that, compared with the major allele homozygote (rs7101916 CC genotype or rs28372683 CC genotype), a significant decreased risk was found in rs7101916 T allele or rs28372683A allele in the male subgroup (OR = 0.734, 95% CI = 0.572–0.941, <italic>P</italic> = 0.015) for rs7101916 and in all subgroup for rs28372683 (all <italic>P</italic> &lt; 0.05, shown in Table <xref rid="Tab4" ref-type="table">4</xref>), after adjusting for gender, age, and the route of infection.<table-wrap id="Tab4"><label>Table 4</label><caption xml:lang="en"><p>Stratified analysis of rs7101916 and rs28372683 among control, spontaneous clearance and persistent infection groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>SNPs</p></th><th rowspan="2"><p>Allele</p></th><th rowspan="2"><p>Subgroups</p></th><th colspan="2"><p>Group (B + C)/Group A</p></th><th colspan="2"><p>Group C/Group B</p></th></tr><tr><th><p>OR (95% CI)<sup>a</sup></p></th><th><p><italic>P</italic><sup>a</sup></p></th><th><p>OR (95% CI)<sup>b</sup></p></th><th><p><italic>P</italic><sup>b</sup></p></th></tr></thead><tbody><tr><td rowspan="9"><p>rs7101916</p></td><td rowspan="9"><p>C/T</p></td><td><p>Age</p></td><td/><td/><td/><td/></tr><tr><td><p>   &lt;55</p></td><td><p>0.891 (0.705–1.125)</p></td><td><p>0.331</p></td><td><p>1.047 (0.727–1.508)</p></td><td><p>0.805</p></td></tr><tr><td><p>   ≥55</p></td><td><p><bold>0.748 (0.611–0.915)</bold></p></td><td><p><bold>0.005</bold></p></td><td><p>0.860 (0.622–1.187)</p></td><td><p>0.359</p></td></tr><tr><td><p>Gender</p></td><td/><td/><td/><td/></tr><tr><td><p>   male</p></td><td><p><bold>0.734 (0.572–0.941)</bold></p></td><td><p><bold>0.015</bold></p></td><td><p>1.125 (0.731–1.731)</p></td><td><p>0.593</p></td></tr><tr><td><p>   female</p></td><td><p>0.842 (0.694–1.021)</p></td><td><p>0.080</p></td><td><p>0.812 (0.606–1.088)</p></td><td><p>0.163</p></td></tr><tr><td><p>Routes of infection</p></td><td/><td/><td/><td/></tr><tr><td><p>   HD</p></td><td><p>0.788 (0.599–1.037)</p></td><td><p>0.089</p></td><td><p>0.925 (0.573–1.494)</p></td><td><p>0.751</p></td></tr><tr><td><p>   Blood donation</p></td><td><p>1.002 (0.746–1.344)</p></td><td><p>0.992</p></td><td><p>0.878 (0.666–1.159)</p></td><td><p>0.359</p></td></tr><tr><td rowspan="9"><p>rs28372683</p></td><td rowspan="9"><p>C/A</p></td><td><p>Age</p></td><td/><td/><td/><td/></tr><tr><td><p>   &lt;55</p></td><td><p><bold>0.563 (0.368–0.862)</bold></p></td><td><p><bold>0.008</bold></p></td><td><p>0.623 (0.316–1.226)</p></td><td><p>0.171</p></td></tr><tr><td><p>   ≥55</p></td><td><p><bold>0.589 (0.402–0.862)</bold></p></td><td><p><bold>0.006</bold></p></td><td><p>0.744 (0.416–1.330)</p></td><td><p>0.318</p></td></tr><tr><td><p>Gender</p></td><td/><td/><td/><td/></tr><tr><td><p>   male</p></td><td><p><bold>0.477 (0.294–0.774)</bold></p></td><td><p><bold>0.003</bold></p></td><td><p>0.780 (0.328–1.859)</p></td><td><p>0.576</p></td></tr><tr><td><p>   female</p></td><td><p><bold>0.640 (0.452–0.906)</bold></p></td><td><p><bold>0.012</bold></p></td><td><p>0.642 (0.384–1.074)</p></td><td><p>0.092</p></td></tr><tr><td><p>Routes of infection</p></td><td/><td/><td/><td/></tr><tr><td><p>   HD</p></td><td><p><bold>0.394 (0.196–0.795)</bold></p></td><td><p><bold>0.009</bold></p></td><td><p>0.596 (0.140–2.532)</p></td><td><p>0.483</p></td></tr><tr><td><p>   Blood donation</p></td><td><p><bold>0.632 (0.461–0.867)</bold></p></td><td><p><bold>0.004</bold></p></td><td><p>0.685 (0.431–1.091)</p></td><td><p>0.111</p></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: CI, confidence interval; HD, hemodialysis; OR, odds ratio.</p><p>Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals.</p><p><sup>a</sup>The <italic>P</italic> value, OR and 95% CIs of group (B + C) versus Group A were calculated on the basis of the binary logistic regression model, adjusted by gender, age and routes of infection in dominant model (CC vs. CT + TT for rs7101916, CC vs. CA + AA for rs28372683).</p><p><sup>b</sup>The <italic>P</italic> value, OR and 95% CIs of group C versus Group B were calculated on the basis of the binary logistic regression model, adjusted by gender, age, routes of infection and HCV genotype in dominant model (CC vs. CT + TT for rs7101916, CC vs. CA + AA for rs28372683).</p><p>Bold type indicates statistically significant results.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Association between <italic>NF-κB</italic> polymorphisms and spontaneous clearance of HCV infection</title><p id="Par19">No association was found between the four SNPs (rs842647, rs7101916, rs12769316 and rs28372683) and spontaneous clearance of HCV in our logistic regression analysis using dominant model, adjusting for gender, age, the route of infection and HCV genotype (all <italic>P</italic> &gt; 0.05, Table <xref rid="Tab3" ref-type="table">3</xref>), or in the further stratification analysis (all <italic>P</italic> &gt; 0.05, Table <xref rid="Tab4" ref-type="table">4</xref>).</p></sec><sec id="Sec14"><title>Cumulative effects of rs7101916 and rs28372683 on the susceptibility of HCV infection</title><p id="Par20">The analysis of combined protective alleles (rs7101916 T allele and rs28372683 A allele) suggested that subjects carried 1–3 protective alleles was associated with a decreased risk of the susceptibility of HCV infection when compared with subjects carried 0 protective allele (all <italic>P</italic> &lt; 0.05, Table <xref rid="Tab5" ref-type="table">5</xref>). Additionally, these two SNPs have trended influence on a decreased risk of the susceptibility of HCV infection after the Cochran–Armitage trend test (OR = 0.641, 95% CI = 0.514–0.799, <italic>P</italic> = 7.9e-5, Table <xref rid="Tab5" ref-type="table">5</xref>). Moreover, after analyzing the combined protective genotypes (rs7101916 TT and rs28372683 AA) on the susceptibility to HCV infection shown in Table <xref rid="Tab6" ref-type="table">6</xref>, we found that carrying 1 protective genotypes offered a significant high protective effect (OR = 0.696, 95% CI = 0.492–0.984, <italic>P</italic> = 0.04).<table-wrap id="Tab5"><label>Table 5</label><caption xml:lang="en"><p>Cumulative effects of combined risk alleles (rs7101916 T and rs28372683 A) on the susceptibility to HCV infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Variables</p></th><th><p>Group A</p></th><th><p>Group (B + C)</p></th><th colspan="2"><p>Group (B + C)/Group A</p></th></tr><tr><th><p>n</p></th><th><p>n</p></th><th><p>OR(95% CI)<sup>a</sup></p></th><th><p><italic>P</italic><sup>a</sup></p></th></tr></thead><tbody><tr><td><p>0</p></td><td><p>302</p></td><td><p>277</p></td><td><p>1</p></td><td/></tr><tr><td><p>1</p></td><td><p>439</p></td><td><p>296</p></td><td><p><bold>0.702 (0.554–0.890)</bold></p></td><td><p><bold>0.003</bold></p></td></tr><tr><td><p>2</p></td><td><p>189</p></td><td><p>94</p></td><td><p><bold>0.543 (0.396–0.747)</bold></p></td><td><p><bold>1.68e-4</bold></p></td></tr><tr><td><p>3</p></td><td><p>31</p></td><td><p>8</p></td><td><p><bold>0.254 (0.111–0.580)</bold></p></td><td><p><bold>0.001</bold></p></td></tr><tr><td><p>4</p></td><td><p>1</p></td><td><p>4</p></td><td><p>3.974 (0.403–39.226)</p></td><td><p>0.237</p></td></tr><tr><td><p>Trend</p></td><td/><td/><td/><td><p><bold>8e-6</bold><sup><bold>b</bold></sup></p></td></tr><tr><td><p>1–4</p></td><td><p>660</p></td><td><p>402</p></td><td><p><bold>0.641 (0.514–0.799)</bold></p></td><td><p><bold>7.9e-5</bold></p></td></tr></tbody></table><table-wrap-foot><p> Abbreviations: HCV, hepatitis C virus; OR, odds ratio; 95% CI, 95% confidence interval.Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B+C): HCV-infected individuals. <sup>a</sup>Logistic regression model, adjusted for gender, age and routes of infection. <sup>b</sup>Cochran–Armitage trend test. Bold type indicates statistically significant results.</p></table-wrap-foot></table-wrap><table-wrap id="Tab6"><label>Table 6</label><caption xml:lang="en"><p>Cumulative effects of combined risk genotypes (rs7101916 TT and rs28372683 AA) on the susceptibility to HCV infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Variables</p></th><th><p>Group A</p></th><th><p>Group (B + C)</p></th><th colspan="2"><p>Group (B + C)/Group A</p></th></tr><tr><th><p>n</p></th><th><p>n</p></th><th><p>OR (95% CI)<sup>a</sup></p></th><th><p><italic>P</italic><sup>a</sup></p></th></tr></thead><tbody><tr><td><p>0</p></td><td><p>302</p></td><td><p>277</p></td><td><p>1</p></td><td/></tr><tr><td><p>1</p></td><td><p>127</p></td><td><p>80</p></td><td><p><bold>0.696 (0.492–0.984)</bold></p></td><td><p><bold>0.040</bold></p></td></tr><tr><td><p>2</p></td><td><p>1</p></td><td><p>4</p></td><td><p>4.112 (0.407–41.595)</p></td><td><p>0.231</p></td></tr><tr><td><p>Trend</p></td><td/><td/><td/><td><p>0.087<sup>b</sup></p></td></tr><tr><td><p>1–2</p></td><td><p>128</p></td><td><p>84</p></td><td><p>0.725 (0.515–1.021)</p></td><td><p>0.065</p></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: HCV, hepatitis C virus; OR, odds ratio; 95% CI, 95% confidence interval.</p><p>Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals.</p><p><sup>a</sup>Logistic regression model, adjusted for gender, age and routes of infection.</p><p><sup>b</sup>Cochran–Armitage trend test.</p><p>Bold type indicates statistically significant results.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Haplotype analysis of rs7101916 and rs28372683 on the susceptibility of HCV infection</title><p id="Par21">The two-locus haplotypes were consisted of rs7101916 and rs28372683 variant alleles. Compared with the most frequent CC haplotype, TC and CA haplotype were significantly associated with the decreased risk of the susceptibility to HCV infection (TC haplotype: OR = 0.68, 95% CI = 0.568–0.813, <italic>P</italic> &lt; 0.001; CA haplotype: OR = 0.604, 95% CI = 0.425–0.858, <italic>P</italic> = 0.005) (Table <xref rid="Tab7" ref-type="table">7</xref>).<table-wrap id="Tab7"><label>Table 7</label><caption xml:lang="en"><p>Haplotype frequencies of rs7101916 and rs28372683.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Variables</p></th><th><p>Group A</p></th><th><p>Group (B + C)</p></th><th colspan="2"><p>Group (B + C)/Group A</p></th></tr><tr><th><p>n</p></th><th><p>n</p></th><th><p>OR (95% CI)<sup>a</sup></p></th><th><p><italic>P</italic><sup>a</sup></p></th></tr></thead><tbody><tr><td><p>CC</p></td><td><p>1045</p></td><td><p>850</p></td><td><p>1</p></td><td/></tr><tr><td><p>TC</p></td><td><p>709</p></td><td><p>424</p></td><td><p><bold>0.680 (0.568–0.813)</bold></p></td><td><p><bold>&lt;0.001</bold></p></td></tr><tr><td><p>CA</p></td><td><p>139</p></td><td><p>68</p></td><td><p><bold>0.604 (0.425–0.858)</bold></p></td><td><p><bold>0.005</bold></p></td></tr><tr><td><p>TA</p></td><td><p>33</p></td><td><p>16</p></td><td><p>0.557 (0.280–1.109)</p></td><td><p>0.086</p></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: HCV, hepatitis C virus; OR, odds ratio; 95% CI, 95% confidence interval.</p><p>Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals.</p><p><sup>a</sup>Logistic regression model, adjusted for gender, age and routes of infection.</p><p>Bold type indicates statistically significant results.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title><italic>In silico</italic> analysis of SNPs function</title><p id="Par22">Rs7101916 is located near the 5′ end of the RelA gene, which contains 11 exons and is mapped to chromosome 11q13.1. Using the SNP Information file (SNPInfo) web server, rs7101916 was predicted to be a transcription factor binding site (TFBS). Combined with the location of rs7101916, this mutation could involve in altering the binding of TF and mediating the transcriptional regulation. Therefore, RelA RNA secondary structures with rs7101916 major allele or minor allele were further predicted through energy minimization using RNAfold web server, based on the latest ViennaRNA Package (Version 2.4.6). The local structure changes are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. The minimum free energy of the centroid secondary structure (a structure with minimal base pair distance) for minor T allele of rs7101916 (−49.90 kcal/mol) was lower than that of major C allele (−44.70 kcal/mol). Results of eQTL analysis indicated that different genotypes of rs7101916 could cause differential mRNA level of ribonuclease H2 subunit C (RNASEH2C) in transformed fibroblasts cells and influence liver fibrosis process after HCV infection.<fig id="Fig2"><label>Figure 2</label><caption xml:lang="en"><p>The influence of rs7101916 on mRNA centroid secondary structures of RelA near the 5′end region. Changes in the local structure were illustrated by the RNAfold Web Server. The arrow indicates the position of the mutation (50 bases upstream and 50 bases downstream from the mutation). The minimum free energy of the mRNA centroid secondary structure (a structure with minimal base pair distance) for wild type and mutant rs7101916 were estimated to be −44.70 kcal/mol (Fig. 2A) and −49.90 kcal/mol (Fig. 2B), respectively. The wild-type and mutant-type sequences are listed below. Underline type indicates the overlapping nucleotide letter that are unreadable in Fig. 2B. The underline bold type indicates the nucleotide difference between the wild and mutant allele. Wild-type sequence: GCGCGUCCGUGUGGAGGCUGGGGCUGACGCACCCCCACCCCAGGCCUCAU<bold><underline>C</underline></bold>CCCAAAGGAGGAUGCUCCACUGCAGGGGGCGGAGUCUUCUCCAGAUGGAG Mutant-type sequence: <underline>GCG</underline>CGUCCGUGUGGAGGCUGGGGCUGACGCACCCCCACCCCAGGCCUCAU<bold><underline>U</underline></bold>CCCAAAGGAGGAUGCUCCACUGCAGGGGGCGGAGUCUUCUCCAGAUGG<underline>AG</underline>.</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41598_2019_47058_Fig2_HTML.png"/></p></fig></p><p id="Par23">Rs28372683 is located in the 3′-untranslated region (3′-UTR) region of RelB gene, which contains 12 exons and is mapped to chromosome 19q13.32. According to the SNPinfo web server, rs28372683 was predicted to be a TFBS or a micro RNA (miRNA) (hsa-miR-1224-3p, hsa-miR-532-3p) binding site, or involved in the exotic splicing (enhancer or silencer). Considering the possible RelB gene expression regulation effect of rs28372683 variation at the translational or post-translational level, RelB RNA secondary structure was further predicted using RNAfold web server. The local structure changes are shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. The minimum free energy of the centroid secondary structure for mutant A allele (corresponded to U allele in Fig. <xref rid="Fig3" ref-type="fig">3</xref>) of rs28372683 (−35.00 kcal/mol) was lower than that of wild C allele (corresponded to G allele in Fig. <xref rid="Fig3" ref-type="fig">3</xref>, −24.30 kcal/mol).<fig id="Fig3"><label>Figure 3</label><caption xml:lang="en"><p>The influence of rs28372683 on mRNA centroid secondary structures of RelB in the 3′-UTR region. Changes in the local structure were illustrated by the RNAfold Web Server. The arrow indicates the position of the mutation (60 bases upstream and 60 bases downstream from the mutation). The minimum free energy of the mRNA centroid secondary structure (a structure with minimal base pair distance) for wild type and mutant rs28372683 were estimated to be −24.30 kcal/mol (Fig. 3A) and −35.00 kcal/mol (Fig. 3B), respectively. The wild-type and mutant-type sequences are listed below. The underline bold type indicates the nucleotide difference between the wild and mutant allele. Wild-type sequence: AGAUUGUACAUAUGGGAGGAGGGGGCAGAUUCCUGGCCCUCCCUCCCCAGACUUGAAGGU<bold><underline>G</underline></bold>GGGGGUAGGUUGGUUGUUCAGAGUCUUCCCAAUAAAGAUGAGUUUUUGAGCCUCCGGGGU Mutant-type sequence: AGAUUGUACAUAUGGGAGGAGGGGGCAGAUUCCUGGCCCUCCCUCCCCAGACUUGAAGGU<bold><underline>U</underline></bold>GGGGGUAGGUUGGUUGUUCAGAGUCUUCCCAAUAAAGAUGAGUUUUUGAGCCUCCGGGGU.</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41598_2019_47058_Fig3_HTML.png"/></p></fig></p><p id="Par24">Rs12769316 is located near the 5′ end of the NF-κB2 gene, which contains 25 exons and is mapped to chromosome 10q24.32. Using the SNPinfo web server, rs12769316 was predicted to be a TFBS and could be involved in transcriptional regulation. Then we also analyzed NF-κB2 RNA secondary structure using RNAfold web server. However, no difference between wild type and mutant type was found (Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM1">1</xref>). The lowest free energy of the centroid secondary structure for the wild C allele (corresponded to G allele in Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM1">1</xref>, −23.40 kcal/mol) of rs12769316 is nearly identical to that of the mutant T allele (corresponded to A allele in Supplementary Fig. <xref ref-type="supplementary-material" rid="MOESM1">1</xref>, −24.40 kcal/mol). Therefore, rs12769316 could not influence the transcriptional control of NF-κB2 gene expressions or HCV infection.</p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p id="Par25">Our study firstly indicated that RelA rs7101916 T allele and RelB rs28372683 A allele were associated with the decreased risk of the susceptibility to HCV infection among the Chinese Han population. Host genetic background strongly influences the susceptibility and the response to HCV infection. Our previous studies, as well as other previous studies, have showed that many genetic variants affect HCV infection immune response and related to different disease outcomes, such as RelA<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, Toll-like receptor 7<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>, interleukin-18<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, human leukocyte antigen class II<sup><xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR36">36</xref></sup>, vitamin D receptor<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup> and estrogen receptor α<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p><p id="Par26">In this study, RelA rs7101916 (located near the 5′ end of the gene) mutant T allele was found to be linked to the protection from HCV infection. RelA gene encoded transcription factor p65, also known as NF-κB p65 subunit, which formed the heterodimeric p65-p50 complex, the most abundant one of the transamination complexes<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. According to the <italic>in silico</italic> analysis in this study, the minimum free energy of the local structure for T allele of rs7101916 was lower than that of C allele. Considering that rs7101916 located near the 5′ end of the RelA gene, it may be a TFBS and influence the binding of TF (according to the SNPInfo), followed by the transcriptional regulation<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. Besides, according to the information from UCSC (<ext-link xlink:href="http://www.genome.ucsc.edu" ext-link-type="url">http://www.genome.ucsc.edu</ext-link>) and the results of eQTL analysis, this SNP located at regulatory elements region, can have possible functions on gene transcription, expression process and influence liver fibrosis process after HCV infection excepting the association with HCV susceptibility. Therefore, the genetic variation of rs7101916 may influence the RelA gene transcriptional regulation and gene expression, subsequently affecting NF-κB pathway activation and the susceptibility to HCV infection.</p><p id="Par27">In our study, RelB rs28372683 (located in the 3′-UTR region of the gene) mutant A allele was associated with the protection from HCV infection. RelB is an important arm of the RelB/p52 NF-κB complex in a non-canonical NF-κB pathway activation through a mechanism dependent on inducible processing of p100<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. According to the results of <italic>in silico</italic> analysis, rs28372683 location could not only bind to the transcription or miRNAs, but also be exotic splicing (enhancer or silencer) site. In addition, the minimum free energy of the centroid secondary structure for A allele of rs28372683 was lower than that of C allele. Therefore, the genetic variation of RelB rs28372683 may be associated NF-κB pathway activation and the susceptibility to HCV infection through potential functional mechanisms.</p><p id="Par28">The results of the cumulative effects and haplotype analyses suggested that the more protective alleles (rs7101916 T and rs28372683 A) subjects carried, the greater the protective effect on the susceptibility of HCV infection exhibited, except that some groups with negative results had too few subjects to detect with sufficient statistical power.</p><p id="Par29">There were no significant relationship of rs842647 and rs12769316 to spontaneous clearance of HCV infection. Rs842647 is located in the intron region of RelB gene. Introns on DNA are transcribed into the precursor RNA, the introns on the RNA are cleaved before the RNA leaves the nucleus for translation, and ultimately not in the mature RNA molecule. Rs12769316 is located 1.5 kb upstream of 5′ of the NF-κB2 gene and was found to be related to NF-κB2 protein and mRNA expression and predicted to be a TFBS. However, we did not find the correlation between rs12769316 and HCV clearance. The reason may be that the SNP is meaningless in our ethnicity and the number of subjects included in the study is insufficient. More studies should be performed to confirm this result.</p><p id="Par30">Several limitations of our study merit consideration. First, it is difficult to acquire the subjects’ exact age and time of the initial infection with HCV, thereby possibly impacting subjects’ immune response and outcomes of HCV infection. Second, the partial lack of HCV genotypes among spontaneous clearance subjects and persistent infection patients could lead to unreliable analysis of the association between NF-κB polymorphisms and spontaneous clearance of HCV infection, especially for the compilation of the genotypes distributions between spontaneous clearance subjects v.s. persistent infection patients. Therefore, more studies were needed to confirm the negative results of the associations between the four SNPs and spontaneous clearance of HCV infection in this study. Direct-acting antiviral (DAA) regimens have reformed the treatment of HCV. Predicting treatment response to an IFN-based regimen is still far from enough. However, the new therapy has not been used extensively because of its unknown adverse effects and expensive costs in developing countries like China. As it was before, PEG-IFN/RBV regimen is still the first-line treatment for patients with HCV type 1 infection in China. Future studies should focus on the relationship between genetic polymorphisms and DAA treatment response.</p><p id="Par31">In conclusion, this study firstly reported that the carriage of RelA rs7101916 T or RelB rs28372683 A was the potential protective factor against HCV infection among the Chinese population. These findings can serve as a reference for the preventive, predictive and therapeutic strategies of HCV infection. Additionally, further epidemiological and functional research on the <italic>NFKB</italic> pathway genetic variants is required.</p></sec></body><back><ack><title>Acknowledgements</title><p>We also thank doctors and the nurses from the Jurong People’s Hospital for helping sample collection and organization of the field investigation. This research would not have been possible without the consent and help of the participants. Grants from the Natural Science Foundation of Jiangsu Province of China (grant numbers: BK20171054, BK20151026); the National Natural Science Foundation of China (Grant Numbers: 81703273, 81502853, 81773499, 61571119); Jiangsu Program for Young Medical Talents (Grant Number: QNRC2016616); and the Medical Innovation Team Project of Jiangsu Province (Grant Number: CXTDA2017023); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).</p></ack><sec sec-type="author-contribution"><title>Author Contributions</title><p>M.Y., Y.Z. and P.H. participated in the design of the study. T.T., H.Z.F. and J.J.W. carried out the surveys and experiments. C.W., T.T., P.H. X.X.S. and A.M.Z. performed the statistical analysis. M.Y., C.W., Y.Z., R.B.Y., J.K.W. and J.L. contributed materials and analytical tools. M.Y., T.T. and P.H. wrote the manuscript and tables. M.Y. prepared the figures. All authors read and approved the final manuscript.</p></sec><sec sec-type="ethics-statement"><sec id="FPar1" sec-type="COI-statement"><title>Competing Interests</title><p id="Par32">The authors declare no competing interests.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>JH</given-names></name><etal/></person-group><article-title xml:lang="en">Urgency to treat patients with chronic hepatitis C in Asia</article-title><source>Journal of gastroenterology and hepatology</source><year>2017</year><volume>32</volume><fpage>966</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1111/jgh.13709</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>AL</given-names></name></person-group><article-title xml:lang="en">Global control of hepatitis C virus</article-title><source>Science</source><year>2015</year><volume>349</volume><fpage>790</fpage><lpage>791</lpage><pub-id pub-id-type="bibcode">2015Sci...349..790C</pub-id><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhtlKltrjI</pub-id><pub-id pub-id-type="doi">10.1126/science.aad1302</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falade-Nwulia</surname><given-names>O</given-names></name><etal/></person-group><article-title xml:lang="en">Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review</article-title><source>Annals of internal medicine</source><year>2017</year><volume>166</volume><fpage>637</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.7326/M16-2575</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naggie</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>AJ</given-names></name></person-group><article-title xml:lang="en">Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs</article-title><source>Annual review of medicine</source><year>2017</year><volume>68</volume><fpage>345</fpage><lpage>358</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28Xhs1SisLzJ</pub-id><pub-id pub-id-type="doi">10.1146/annurev-med-052915-015720</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlotsky</surname><given-names>JM</given-names></name></person-group><article-title xml:lang="en">The end of the hepatitis C burden: Really?</article-title><source>Hepatology</source><year>2016</year><volume>64</volume><fpage>1404</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1002/hep.28758</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balagopal</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Thio</surname><given-names>CL</given-names></name></person-group><article-title xml:lang="en">IL28B and the control of hepatitis C virus infection</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>1865</fpage><lpage>1876</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXhsFaktrvK</pub-id><pub-id pub-id-type="doi">10.1053/j.gastro.2010.10.004</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKiernan</surname><given-names>SM</given-names></name><etal/></person-group><article-title xml:lang="en">Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source</article-title><source>Hepatology</source><year>2004</year><volume>40</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2cXmtlSgtbo%3D</pub-id><pub-id pub-id-type="doi">10.1002/hep.20261</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Discovering NF-κB</article-title><source>Cold Spring Harbor perspectives in biology</source><year>2009</year><volume>1</volume><fpage>a000026</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a000026</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><article-title xml:lang="en">NF-κB regulation in the immune system</article-title><source>Nature Reviews Immunology</source><year>2002</year><volume>2</volume><fpage>725</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD38XnsVGqsbg%3D</pub-id><pub-id pub-id-type="doi">10.1038/nri910</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name></person-group><article-title xml:lang="en">NF-κB: a key role in inflammatory diseases</article-title><source>The Journal of clinical investigation</source><year>2001</year><volume>107</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD3MXitVOhtg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1172/JCI11830</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>May</surname><given-names>MJ</given-names></name><name><surname>Kopp</surname><given-names>EB</given-names></name></person-group><article-title xml:lang="en">NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses</article-title><source>Annual review of immunology</source><year>1998</year><volume>16</volume><fpage>225</fpage><lpage>260</lpage><pub-id pub-id-type="coi">1:CAS:528:DyaK1cXislygtL0%3D</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.16.1.225</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>AS</given-names><suffix>Jr.</suffix></name></person-group><article-title xml:lang="en">The NF-κB and IκB proteins: new discoveries and insights</article-title><source>Annual review of immunology</source><year>1996</year><volume>14</volume><fpage>649</fpage><lpage>681</lpage><pub-id pub-id-type="coi">1:CAS:528:DyaK28XitlCgtbc%3D</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.14.1.649</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>QM</given-names></name></person-group><article-title xml:lang="en">The IKK NF-κB system: a treasure trove for drug development</article-title><source>Nature reviews Drug discovery</source><year>2004</year><volume>3</volume><fpage>17</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2cXpvFKqug%3D%3D</pub-id><pub-id pub-id-type="doi">10.1038/nrd1279</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>G</given-names></name><name><surname>Waris</surname><given-names>G</given-names></name><name><surname>Tanveer</surname><given-names>R</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB</article-title><source>Proceedings of the National Academy of Sciences</source><year>2001</year><volume>98</volume><fpage>9599</fpage><lpage>9604</lpage><pub-id pub-id-type="bibcode">2001PNAS...98.9599G</pub-id><pub-id pub-id-type="coi">1:CAS:528:DC%2BD3MXmtlCnur0%3D</pub-id><pub-id pub-id-type="doi">10.1073/pnas.171311298</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caamano</surname><given-names>J</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><article-title xml:lang="en">NF-κB family of transcription factors: central regulators of innate and adaptive immune functions</article-title><source>Clinical microbiology reviews</source><year>2002</year><volume>15</volume><fpage>414</fpage><lpage>429</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD38XlvV2msbY%3D</pub-id><pub-id pub-id-type="doi">10.1128/CMR.15.3.414-429.2002</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MH</given-names></name><name><surname>Hong</surname><given-names>JT</given-names></name></person-group><article-title xml:lang="en">Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches</article-title><source>Cells</source><year>2016</year><volume>5</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.3390/cells5020015</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title xml:lang="en">NF-κB Pathway in autoinflammatory diseases: dysregulation of protein modifications by ubiquitin defines a new category of autoinflammatory diseases</article-title><source>Frontiers in immunology</source><year>2017</year><volume>8</volume><fpage>399</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00399</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Taniguchi, K. &amp; Karin, M. NF-κB, inflammation, immunity and cancer: Coming of age. <italic>Nature Reviews Immunology</italic> (2018).</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Genetic variations in NF-κB were associated with the susceptibility to hepatitis C virus infection among Chinese high-risk population</article-title><source>Scientific reports</source><year>2018</year><volume>8</volume><pub-id pub-id-type="bibcode">2018NatSR...8..104T</pub-id><pub-id pub-id-type="doi">10.1038/s41598-017-18463-y</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>HZ</given-names></name><etal/></person-group><article-title xml:lang="en">Genetic variation on the NFKB1 genes associates with the outcomes of HCV infection among Chinese Han population</article-title><source>Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases</source><year>2018</year><volume>65</volume><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXhsVGhurzL</pub-id><pub-id pub-id-type="doi">10.1016/j.meegid.2018.07.031</pub-id><pub-id pub-id-type="pmid">30056167</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>R</given-names></name><etal/></person-group><article-title xml:lang="en">Variants of the RELA gene are associated with schizophrenia and their startle responses</article-title><source>Neuropsychopharmacology</source><year>2011</year><volume>36</volume><fpage>1921</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXovFOrt7w%3D</pub-id><pub-id pub-id-type="doi">10.1038/npp.2011.78</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Brown</surname><given-names>ZK</given-names></name><name><surname>Van Nostrand</surname><given-names>EL</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name></person-group><article-title xml:lang="en">The inflammatory transcription factors NFκB, STAT1 and STAT3 drive age-associated transcriptional changes in the human kidney</article-title><source>PLoS genetics</source><year>2015</year><volume>11</volume><fpage>e1005734</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1005734</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><etal/></person-group><article-title xml:lang="en">Genetic polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: a nested case–control study in Shanghai, China</article-title><source>BMJ open</source><year>2014</year><volume>4</volume><fpage>e004427</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-004427</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edenberg</surname><given-names>HJ</given-names></name><etal/></person-group><article-title xml:lang="en">Association of NFKB1, which encodes a subunit of the transcription factor NF-κB, with alcohol dependence</article-title><source>Human molecular genetics</source><year>2007</year><volume>17</volume><fpage>963</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm368</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>G</given-names></name><etal/></person-group><article-title xml:lang="en">Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery</article-title><source>Lymphatic research and biology</source><year>2014</year><volume>12</volume><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXks12gsbs%3D</pub-id><pub-id pub-id-type="doi">10.1089/lrb.2013.0024</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Du, J. <italic>et al</italic>. Polymorphisms of NF-κB family genes are associated with development of multiple myeloma and treatment outcome in patients undergoing bortezomib-based regimens. <italic>Haematologica</italic>, haematol. 2010.030577 (2011).</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byun</surname><given-names>E</given-names></name><etal/></person-group><article-title xml:lang="en">Cytokine polymorphisms are associated with daytime napping in adults living with HIV</article-title><source>Sleep medicine</source><year>2017</year><volume>32</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2016.12.021</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aouizerat</surname><given-names>BE</given-names></name><etal/></person-group><article-title xml:lang="en">Phenotypic and molecular evidence suggests that decrements in morning and evening energy are distinct but related symptoms</article-title><source>Journal of pain and symptom management</source><year>2015</year><volume>50</volume><fpage>599</fpage><lpage>614. e593</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2015.05.008</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Association</surname><given-names>WM</given-names></name></person-group><article-title xml:lang="en">World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title><source>Jama</source><year>2013</year><volume>310</volume><fpage>2191</fpage><pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacherjee</surname><given-names>V</given-names></name><etal/></person-group><article-title xml:lang="en">Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6</article-title><source>Journal of General Virology</source><year>1995</year><volume>76</volume><fpage>1737</fpage><lpage>1748</lpage><pub-id pub-id-type="coi">1:CAS:528:DyaK2MXmsl2lt74%3D</pub-id><pub-id pub-id-type="doi">10.1099/0022-1317-76-7-1737</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Sex-specific association between X-linked Toll-like receptor 7 with the outcomes of hepatitis C virus infection</article-title><source>Gene</source><year>2014</year><volume>548</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXhtFygsb3K</pub-id><pub-id pub-id-type="doi">10.1016/j.gene.2014.07.040</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Toll-like receptor 7 variations are associated with the susceptibility to HCV infection among Chinese females</article-title><source>Infection, Genetics and Evolution</source><year>2014</year><volume>27</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXhtlartLnP</pub-id><pub-id pub-id-type="doi">10.1016/j.meegid.2014.07.034</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Association of interleukin-18 gene polymorphisms with the outcomes of hepatitis C virus infection in high-risk Chinese Han population</article-title><source>Immunology letters</source><year>2013</year><volume>154</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXhsFOnsrjO</pub-id><pub-id pub-id-type="doi">10.1016/j.imlet.2013.08.007</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group><article-title xml:lang="en">Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population</article-title><source>International journal of molecular sciences</source><year>2014</year><volume>15</volume><fpage>9826</fpage><lpage>9843</lpage><pub-id pub-id-type="doi">10.3390/ijms15069826</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Human leukocyte antigen class II alleles are associated with hepatitis C virus natural susceptibility in the Chinese population</article-title><source>International journal of molecular sciences</source><year>2015</year><volume>16</volume><fpage>16792</fpage><lpage>16805</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhvValtbzN</pub-id><pub-id pub-id-type="doi">10.3390/ijms160816792</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P</given-names></name><etal/></person-group><article-title xml:lang="en">The relationship between human leukocyte antigen-DP/DQ gene polymorphisms and the outcomes of HCV infection in a Chinese population</article-title><source>Virology journal</source><year>2017</year><volume>14</volume><pub-id pub-id-type="doi">10.1186/s12985-017-0901-7</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Vitamin D level and vitamin D receptor genetic variations contribute to HCV infection susceptibility and chronicity in a Chinese population</article-title><source>Infection, Genetics and Evolution</source><year>2016</year><volume>41</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XmtFehtLo%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.meegid.2016.03.032</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M-P</given-names></name><etal/></person-group><article-title xml:lang="en">Genetic variations in vitamin D receptor were associated with the outcomes of hepatitis C virus infection among Chinese population</article-title><source>Journal of human genetics</source><year>2016</year><volume>61</volume><fpage>129</fpage><pub-id pub-id-type="bibcode">2016rsia.book.....W</pub-id><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XjsFGrsL4%3D</pub-id><pub-id pub-id-type="doi">10.1038/jhg.2015.117</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Association of genetic variants in estrogen receptor α with HCV infection susceptibility and viral clearance in a high-risk Chinese population</article-title><source>European journal of clinical microbiology &amp; infectious diseases</source><year>2014</year><volume>33</volume><fpage>999</fpage><lpage>1010</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXjtleqtQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1007/s10096-013-2038-y</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottagui-Tabar</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Identification of functional SNPs in the 5-prime flanking sequences of human genes</article-title><source>BMC genomics</source><year>2005</year><volume>6</volume><pub-id pub-id-type="doi">10.1186/1471-2164-6-18</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>G</given-names></name><etal/></person-group><article-title xml:lang="en">SNPs in human miRNA genes affect biogenesis and function</article-title><source>Rna</source><year>2009</year><volume>15</volume><fpage>1640</fpage><lpage>1651</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1MXhtVyitb3E</pub-id><pub-id pub-id-type="doi">10.1261/rna.1560209</pub-id></mixed-citation></ref></ref-list></ref-list><app-group><app id="App1"><sec id="Sec18"><title>Supplementary information</title><p id="Par33"><supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41598_2019_47058_MOESM1_ESM.doc" mimetype="application" mime-subtype="msword"><caption xml:lang="en"><p>Supplementary Information</p></caption></media></supplementary-material></p></sec></app></app-group><notes notes-type="ESMHint"><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at <ext-link xlink:href="https://doi.org/10.1038/s41598-019-47058-y" ext-link-type="doi">https://doi.org/10.1038/s41598-019-47058-y</ext-link>.</p></notes><notes notes-type="Misc"><p><bold>Publisher’s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Science, Humanities and Social Sciences, multidisciplinary</facet-value><facet-value count="1">Science, multidisciplinary</facet-value></facet><facet name="keyword"/><facet name="pub"><facet-value count="1">Scientific Reports</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">China</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
